

CURRICULUM VITAE

Norwood Oakley Hill, M.D.

EDUCATION AND DEGREES:

Yale University New Haven, Connecticut	B.S. (Chemistry)	1957
Baylor University College of Medicine Houston, Texas	M.D.	1961

BAYLOR COLLEGE OF MEDICINE STUDENT RESEARCH FELLOWSHIPS:

Summer 1958: Medical Research Foundation of Texas Medical Student Research Fellowship; Chromatography of DNA, Department of Biochemistry, Mentors Drs. Clark Griffin and Sol Kit

Summer 1959: Department of Virology and Epidemiology Medical Student Research Fellowship; The Application of Fluorescent Microscopy (With Labeled Antibodies) to Viral Diagnostics, Mentors: Drs. Joseph L. Melnick and Heather D. Mayor

Summer 1960: Department of Virology and Epidemiology Medical Student Research Fellowship; Senior Thesis: Utilization of Acridine Orange to Search for Virus-Like Inclusions in Tumor Cells, Mentors: Drs. Joseph L. Melnick and Heather D. Mayor

RESIDENCY AND MILITARY SERVICE:

Internship	1961-1962: Jefferson Davis Hospital, Houston, Texas
Resident-Internal Medicine	1962-1963: Jefferson Davis-Ben Taub Hospitals, Houston, Texas
Medical Officer (Captain)	1963-1965: Randolph Air Force Base, Texas
Resident-Internal Medicine	1965-1967: Parkland Hospital, Dallas, Texas

PROFESSIONAL APPOINTMENTS:

Wadley Institutes of Molecular Medicine:

Clinical Systems Analyst: 1967-1990

Hematology and Oncology Research Associate: 1967-1976

Medical Director of Wadley Blood Bank: 1968-1990

President and Trustee, Wadley Institutes of Molecular Medicine: 1976-1990

Professional Organization Positions:

Board of Directors, American Association of Blood Banks: 1972-1977

Vice-President, South Central Association of Blood Banks, 1975

President South Central Association of Blood Banks, 1977

Board of Scientific Advisors-Immuno Modulators Laboratories, Inc.

Dallas County Medical Society-Blood Bank Committee, 1968-1990

Editorial Board for Journal of Interferon Research

Memberships:

American Medical Association

Texas Medical Association

Dallas County Medical Society

American Association of Blood Banks

American Association for the Advancement of Science

South Central Association of Blood Banks

American Society of Hematology

International Society of Hematology

American Society for Clinical Oncology

American Academy of Medical Directors

PUBLICATIONS AND PRESENTATIONS:

1. Mayor HD, and Hill NO: Acridine Orange Staining of a single Stranded DNA Bacteriophage. *Virology*, 14 (June 1961), 246.
2. Abu-Nassar H, Hill NO, Fred HL, and Yow EM: Cutaneous Manifestations of Gonococemia. *Archives of Internal Medicine*, 112 (1963).
3. Hill, N.O.: Reflections and Prospectives of hospital and Clinical Automation From the Standpoint of a Practicing Physician. The Third Annual Goddard Computer Science Institute Biomedical Computing Symposium, December 11, 1967.
4. Hill JM, Roberts J, Loeb E, MacLellan A, Khan A, Shields W, and Hill NO: Clinical Application of L-Asparaginase. A Wadley Institutes Symposium-The Development of L-Asparaginase, April 26-27, 1968.
5. Khan A, Loeb E, MacLellan A, Hill NO, and Hill JM: Coagulopathy During L-Asparaginase Therapy. V Congress of the Asian and Pacific Division of the International Society of Hematology, Istanbul, Turkey, p. 174, 1969.
6. Hill NO, Hill JM, Loeb E, MacLellan A, Alexander TR, Khan A, Adachi M: Tratamiento de Leucemias Agudas Mediante la Depression de Aminoacidos-Soebeitiro de la Revista. *Sociedad Mexicana de Hematologica* 1:23, 1969.
7. Hill JM, Loeb E, MacLellan A, Khan A, Roberts J, Shields W, and Hill NO: Response to Highly Purified L-Asparaginase during Therapy of Acute Leukemia. *Can. Res. Vol. 29*, 1969.
8. Hill NO, Ridgway H, and Speer RJ: Coagulation Testing in the Surgical Patient. Delivered before the Surgical Section of the Texas Medical Association, May 1, 1970. *Texas Medicine*, December 1970, Vol. 66, No. 12, pp. 54-57.
9. Loeb E, Hill JM, Hill NO, MacLellan A, Khan A, Alexander RT, and Adachi M: Treatment of Acute Leukemia with L-Asparaginase. Proceedings VI International Congress of Chemotherapy, 2:667-1970. Published in *Recent Results in Cancer*, 33:204, 1970.
10. Hill JM, Loeb E, MacLellan A, Hill NO, Khan A, and Speer RJ: Asparaginase Therapy: Clinical and Experimental Observations on Complications and Side Effects. *Wadley Medical Bulletin*, Vol. 1, No. 1.

11. Khan A, Loeb E, Hill NO, MacLellan A, and Hill JM: L-Asparaginase and Immune reactions in Man. American Society of Hematology, Puerto Rico, December, 1970, p. 92.
12. Hill NO: Evaluation of the Blood Coagulation Mechanism. Wadley Medical Bulletin, Vol. 1, No. 1, October 1970.
13. Hill JM, Khan A, Loeb E, MacLellan A, and Hill NO: Probable Cures in Acute Leukemia. Wadley Medical Bulletin, Vol. 1, No. 2: 21-26, January, 1971.
14. Hill NO: Hepatitis Testing at Wadley Blood Bank. Wadley Medical Bulletin, Vol. 1, No. 2, January 1971.
15. Hill JM, Loeb E, MacLellan A, Khan, A, and Hill, NO: Asparaginase Therapy: Clinical Results in Acute Leukemia and Other Malignant Diseases. (Abstract) Wadley Medical Bulletin, Vol. 1, No. 2, January, 1971.
16. Hill JM, Loeb E, MacLellan A, Khan, A, and Hill, NO: Asparaginase Therapy: Clinical Results in Acute Leukemia and Other Malignant Diseases. Presented Before Colloques Internationaux Du Centre National De La Recherche Scientifique. No.197. Symposium International Sur La L-Asparaginase. Paris, November 28-30, 1970. Published in Conditions Du Centre National De La Recherche Scientifique, Paris, 15: 273-280, 1971.
17. Hill NO: Fresh Blood: Myth and Reality. Wadley Medical Bulletin, Vol. 1, No. 4, July 1971.
18. Khan A, Hill JM, Loeb E, MacLellan A, and Hill NO: Pharmacology and Clinical Uses of L-Asparaginase. Wadley Medical Bulletin, Vol. 1, No. 4, July, 1971.
19. Hill JM, Speer RJ, Loeb E, MacLellan A, Hill NO and Khan A: Clinical Experience with Cis-Platinous Diammino Dichloride. Presented before the VIIth International Congress of Chemotherapy, Prague, Czechoslovakia, 1971. Published in: Advances in Antimicrobial and Antineoplastic Chemotherapy, Vol. II, pp255-257, University Park Press, Baltimore, 1972.
20. Hill NO: Coagulation. Presented before the South Central Association of Blood Banks, March, 1972.
21. Cardona F, Hill JM, Loeb E, MacLellan A, Hill NO, Khan A: Combination Chemotherapy of Squamous Cell Carcinoma with

- Cis-Platinous Diamminochloride", Wadley Medical Bulletin, Vol. 2, No. 3, July, 1972.
22. Hill NO: Blood Component Therapy. Annals of Internal Medicine, Vol. 77, No. 2, p. 484, September, 1972.
23. Hill JM, Loeb E, Hill NO, Khan A, Albayrak A: Treatment of Acute Leukemia. Wadley Medical Bulletin 2(4):63-76, 1972.
24. Hill JM, Loeb E, Speer RJ, MacLellan A, and Hill NO, Cis-Platinous Diammino Dichloride (PDD) Therapy of Various Malignant Disease. Proc. Am. Assoc. Cancer Res. 13:20, 1972.
25. Hill JM, Loeb E, MacLellan A, Khan A, Hill NO: Terapia con Asparaginasa: Resultados Clinicos en la Leucemia Aguda y en Otras Enfermedades Malignas IX Congress Mexicano de Hematologia y Transfusiones, Mexico, D.F., 1972. Jornadas Internacionales de la Sociedad Mexicana de Hematologia 1972; pp. 19-27.
26. Hill NO: Evaluation of the Blood Coagulation Mechanism. Journal of the South Central Association of Blood Banks, Vol. 16, No. 1, Jan/Feb, 1973.
27. Loeb E, Hill JM, MacLellan A, Hill NO, Khan A, Speer RJ: Five Year Experience with L-Asparaginase in the Treatment of Acute Leukemias. Wadley Medical Bulletin, 2(2): 23-32, 1972.
28. Albayrak A, and Hill NO: Disseminated Intravascular Coagulation in Malignant Diseases. Wadley Symposium on Malignant Diseases, March 10, 1973.
29. Khan A, Hill JM, Loeb E, MacLellan A, Albayrak A, and Hill, N.O: Combination Chemotherapy of Disseminated Cancer. Wadley Symposium on Malignant Diseases, March 10, 1973.
30. MacLellan A, Rouby E, Hill JM, Khan A, and Hill NO: Combination Chemotherapy in Hodgkins Disease. Wadley Medical Bulletin, 3:43, 1973.
31. Loeb E, Hill JM, MacLellan A, Hill NO, and Khan A: Further Clinical Experiences with Cis-Platinous Diamminodichloride. Presented at the 8th International Congress of Chemotherapy in Athens, Greece September 8-14, 1973. Progress in Chemotherapy (editor) GD Kaikos, III:680-686, 1974.
32. Khan A, Hill JM, Loeb E, MacLellan A, Hill NO: Management of Chediak-Higashi Syndrome with Transfer Factor. American Journal of Diseases of Childhood, Vol. 126, December, 1973.

33. Hill JM, Loeb E, Khan A, Hill NO, MacLellan A: Recent Advances in Hematology. La Revista de la Sociedad Mexicana de Hematologia IV:131, 1974.
34. Khan A, Hill JM, Loeb E, MacLellan A, Albayrak A, and Hill, N.O., Combination Chemotherapy of Disseminated Human Cancer. Wadley Medical Bulletin, Vol. 4, No. 1, January 1974.
35. Khan A, Hill JM, Loeb E, MacLellan A, Albayrak A, Hill NO: Chemotherapy of Disseminated Cancer with Multiple Agents. Progress in Chemotherapy (editor) G.D. Kaikos, III:632-625, 1974.
36. Hill JM, Loeb E, Khan A, Hill NO, and MacLellan A: Recientes Adelantos en Hematologia. Journal of the Mexican Society of Hematology, Jan-March, 1974, No. 13.
37. Hill JM, Loeb E, MacLellan A, Khan A, Hill NO, and King., J: Acute Myelogenous Leukemia, Results of Enzyme and Chemotherapy. Presented at XV Congress of the International Society of Hematology, Jerusalem, Israel, September 1-6, 1974.
38. Khan A, Hill JM, Loeb E, Hill NO, Thaxton S: Cellular Immunity to Hodgkins Tissue in Patients and Their Contacts, Wadley Medical Bulletin, 4:82-86, 1974.
39. Khan A, Hill NO, Hill JM, Loeb E, MacLellan A, Comparini S: and Goble P: Prolonged Leucapheresis in Chronic Granulocytic Leukemia. Presented at the International Symposium on Leukocyte Separation and Transfusion, London, England, September 9-11, 1974. In: Leukocytes: Separation, Collection and Transfusion, pp 519-524, Editors: Goldman JM and Lowenthal RM, Academic Press, 1975.
40. Hill NO, Khan A, Hill JM, Loeb E, MacLellan A, and Dandonna, S. Granulocyte Preparation by Continuous Flow Filtration Leucapheresis. Presented at the International Symposium on Leukocyte Separation and Transfusion, London, England, September 9-11, 1974. In: Leukocytes: Separation, Collection and Transfusion, pp 168-173, Editors: Goldman JM and Lowenthal RM, Academic Press, 1975.
41. Khan A, Hill JM, Loeb E, MacLellan A, and Hill NO: Reconstitution of Cellular Immunity in Hodgkins Disease with Transfer Factor. Recent Results in Cancer Research, Vol. 49: 74-80, 1974.

42. Cifuentes E, MacLellan A, Khan A, Martin J, Loeb E, Hill JM, and Hill NO: Leukemic Reticuloendotheliosis. Wadley Medical Bulletin, Vol. 4, No. 4, Oct., 1974.
43. Loeb E, Hill JM, MacLellan A, Hill NO, Khan A, King J, Speer RJ, and Ridgway H: Cis-Platinum Diamminodichloride in the Treatment of Squamous Cell Carcinoma and Other Malignant Diseases. Wadley Medical Bulletin, 5(2):281-295, 1975.
44. Hill JM, Loeb E, MacLellan A, Hill NO, Khan A, and Kogler J: Further Clinical Experience with Cis-Platinum Coordination Compounds in the Therapy of Various Malignant Diseases. Presented before the Amer. Chem. Soc. 30th Annual Meeting (Southwestern Region), Houston, Texas, December, 1974.
45. Khan A, Wakasugi K, Takashi K, Osamura S, Hill NO: Changes in Responses to Mitogens and Other Lymphocyte Marker in Stored Blood. 4th International Meeting of the International Society for Experimental Hematology, Split, Yugoslavia, September 1975.
46. Hill NO: The Use of Rejuvenated Frozen Blood. Presented at the South Central Association of Blood Banks 17th Annual Meeting, March 12-14, 1975, New Orleans, Louisiana.
47. Hill JM, Loeb E, MacLellan A, Khan A, Hill NO, King J: Acute Myelogenous Leukemia: Results of Enzyme and Chemotherapy. Wadley Medical Bulletin, Vol. 5, No. 2, 1975.
48. Hill JM, Loeb E, MacLellan A, Hill NO, Khan A, King J: Clinical Studies of Platinum Coordination Compounds in the Treatment of Various Malignant Diseases: Cancer Chemotherapy Reports, Part I, Vol. 59, 647-659. No. 3, May/June, 1975.
49. Hill JM, MacLellan A, Loeb E, Khan A, Hill NO, King J: Complete Remission in Acute Myelogenous Leukemia Following Intravenous Malonato 1,2-Diaminocyclohexane Platinum(II), Case Report. Wadley Medical Bulletin, Vol. 5, No. 4, October, 1975.
50. Khan A, Hill JM, Grater Wm, Loeb E, MacLellan A, Hill NO: Atopic Hypersensitivity to cis-Dichlorodiammineplatinum(II) and other Platinum Complexes. Cancer Research, 35, 2766-2700, October, 1975.
51. Hill JM, Speer RH, Loeb E, Pardue A, Hill NO, Ridgway H, Khan A, Dorn G, King J, Land G, Hill RW: Team Approach to Cancer Therapy. Wadley Medical Bulletin, 6(4):87-102, 1976.

52. Khan A, Hill NO, Loeb E, Hill JM, and MacLellan A: Current Status of Ongoing Studies with Platinum Compounds. New Drug Liaison Meeting, National Cancer Institute, Bethesda, Maryland, May, 1976.
53. Loeb E, Hill JM, MacLellan A, Hill NO, Khan A, Speer RJ, Ridgway H: Cis-Platinum Diamminodichloride in the Treatment of Squamous Cell Carcinoma and other Malignant Diseases. Wadley Medical Bulletin, 5:281, 1975.
54. Hill JM, Loeb E, MacLellan A, Hill NO, Khan A, King J: Clinical Studies of Platinum coordination Compounds in the Treatment of Various Malignant Diseases. Cancer Chemotherapy Reports, 59:647-658, 1975.
55. Khan A, Hill NO, Hill JM, Loeb E, MacLellan A, Comparini S, Goble, P: Repeated Leucapheresis in Chronic Granulocytic Leukemia. In Leucocytes: Separation, Collection, and Transfusion (editor) Goldman and Lowenthal, Academic Press, London, England, 1975.
56. Hill NO, Khan A, Hill JM, Loeb E, MacLellan A, and Dandona S: Granulocyte Preparation by Continuous Flow Filtration Leucapheresis. In Leucocytes: Separation, Collection and Transfusion (editor) Goldman and Lowenthal, Academic Press, London, England, 1975.
57. Khan A, Thaxton S, Hill JM, Hill NO, Loeb E, MacLellan A, Clinical Trials with Transfer Factor. Transfer Factor: Basic Properties and Clinical Applications (editor) Ascher, Gottlieb, Kirkpatrick, Academic Press, p. 583, 1976.
58. Zaharia L, Hill JM, Loeb E, MacLellan A, Hill NO: Systemic Lupus Erythematosus in Twin Sisters Following Ten Years of Hyperglobulinemic Purpura (Waldenstrom). Acta Medica Scand, 199:429, 1976.
59. Zaharia L, Hill JM, Khan A, Loeb E, MacLellan A, Hill NO: Filtration Leukapheresis for Granulocyte Transfusions. Wadley Medical Bulletin, Vol. 6, No. 1, Jan. 1976.
60. Loeb E, Hill JM, Pardue A, Hill NO, Khan A, King J: Solid Tumor Experience with Newer Platinum Coordination Compounds. Proceedings of the Third International Symposium on Platinum Coordination Complexes in Cancer Chemotherapy. J. Clin. Hem. Onc. 7:701, 1976.

61. Hill JM, Loeb E, Pardue A, Khan A, Hill NO, King J, and Hill, R.W. Platinum Coordination Compounds in the Treatment of Acute Leukemia and Other Malignant Diseases with Particular Reference to Malonato 1,2-Diaminocyclohexane Platinum(II). Proceedings of the Third International Symposium on Platinum Coordination Complexes in Cancer Chemotherapy. J. Clin. Hem. Onc. 7:681, 1976.
62. Hill NO, Comparini S, Dorn G, Pardue A: Administration of Human Leukocyte Interferon in a Patient with Acute Myelogenous Leukemia. Interferon Scientific Memoranda, July, 1977.
63. Hill NO, Loeb E, Pardue A, Khan A, Dorn G, Comparini S, and Hill JM: Leukocyte Interferon Production and its Effectiveness in Acute Lymphatic Leukemia. J. Clin. Hem. Onc., 8:66, 1978.
64. Khan A, Burt S, and Hill NO: Demonstration of a Unique Surface Antigen (sigma) on Sezary Cells. Blood 50, Supplement 1 (abstract) 1977.
65. Khan A, Wakasugi K, Hill N, Komezi T, Osamura S: Changes in the Immunocompetence and Surface Markers of Lymphocytes in Stored Blood. Exp. Hemat. 5, 8-12, 1977.
66. Khan A, Boettcher J, Garrison O, Antonetti A, Graham S, Hill NO: Enhancement of E-Rosettes with Interferon. Interferon Scientific Memoranda, November, 1977.
67. Khan A, Sellars W, Grater Wm, Graham M, Pflanzner J, Antonetti A, Bailey J, Hill NO: The Usefulness of Transfer Factor in Asthma Associated with Frequent Infections. Annals of Allergy, Vol. 40., No. 4, April, 1978.
68. Hill NO, Burnside S: Importance of Supportive Granulocyte Transfusions During Antileukemia Chemotherapy. Wadley Medical Bulletin, Vol. 8, No. 3, July, 1978.
69. Hill NO, Loeb E, Pardue A, Khan A, Dorn G, Hill JM: Responsiveness of Acute Lymphocytic Leukemia to High Dose Leukocyte Interferon. Presented at The International Society of Hematology and International Society of Blood Transfusion, Paris, France, July, 1978.
70. Khan A, Boettcher J, Garrison O, Antonetti A, Graham S, Hill NO: In Vivo Induction of Antiviral Activity by Immunoepitope and Transfer Factor. II. E-Rosette Enhancement by Immunoepitope and Interferon. In: Immunotherapy of Malignant Diseases, (ed) H.

Rainer, F.K. Shattauer. Verlag, Stuttgart-New York, pp364-372, 1978.

71. Hill NO, Loeb, E, Pardue A, Dorn G, Khan A, and Hill JM: Human Leukocyte Interferon: Preparation and Therapeutic Trials in Malignancy. Presented at the Advanced Component Seminar sponsored by Haemonetics Res. Inst., Boston, Mass. 1979.

72. Hill NO, Loeb E, Dorn G, Khan A, Hill JM: Interferon Therapy of Leukemia and Other Malignancies: Very High Dose Requirement for Antileukemic Effects. Presented at the International Workshop on Interferon, New York, New York, March, 1979.

73. Hill NO, Loeb, E, Pardue A, Dorn GL, Khan A, Hill, JM: Response of Acute Leukemia to Leukocyte Interferon. J. Clin. Hem. Onc., Vol. 9, No.1, 1979.

74. Hill NO, Loeb E, Pardue A, Khan A: Therapeutic Studies on Lymphapheresis and Plasmapheresis. Presented at the National Pheresis Seminar, San Francisco, California, June 1979.

75. Hill NO, Khan A, Loeb E, Pardue A, Aleman C, Dorn G, Hill JM: Clinical Trials of High Dose Human Leukocyte Interferon. Presented at the International Symposium on Interferon, Wadley Institutes of Molecular Medicine, Dallas, Texas, October 18-20, 1979.

76. Hill NO, Loeb E, Pardue A, Dorn G, Aleman C, Khan A, Hill JM: Production and Clinical Trials of Very High Dose Human Leukocyte Interferon. Presented at II Congreso Latino Americano de Hematologia, Villahermosa, Mexico, November 11,16, 1979.

77. Khan A, Kiker C, Schpock S, and Hill NO: Monocyte Chemotactic Factor (Human) as a By-Product of Large Scale Interferon Production. FASEB Meeting, Anaheim, Calif., April, 1980, Federation Proceedings (abstract) Part II, #4678, 1980.

78. Kiker C, Khan A, Pakuszewski D, and Hill NO: Procurement of Monocyte Chemotactic Factor During Interferon Production. International Society for Experimental Hematology Meeting, Dallas, Texas. Exp. Hem. 8:, Supplement 7, Abstract #64, 1980.

79. Khan A, Hogan S, Duvall J, Kiker C, Gray L, Chen R, and Hill NO: The Effect of Ozone and the Use of Horse Serum in the Hybridoma Technique: International Society for Experimental Hematology Meeting, Dallas, Texas. Exp. Hem. 8: Supplement 7, Abstract #85, 1980.

80. Duvall J, Khan A, Hill NO, Ground M, Muntz D, and Lanius R: A Computer-Assisted Micro-Dye Uptake Human Interferon Assay. In Interferon: Properties and Clinical Uses (editor) Khan Hill and Dorn. Leland Fikes Foundation Press, Dallas, Texas pp. 667-680, 1980.

81. Hill NO, Khan A, Loeb E, Pardue A, Aleman C, Dorn G, and Hill JM: The In Vivo Effects of Interferon on Human Immune Responses: Low Interferon Production Associated with T-Cell Defects. In Interferon: Properties and Clinical Uses. (editors) Khan, Hill, and Dorn. Leland Fikes Foundation Press, pp. 681-691, 1980

82. Hill NO: Interferon: A Medical Overview. Presented at American Blood Resources Association, February 25, 1980, Arlington, Virginia.

83. Hill JM, Loeb E, Pardue A, Aleman C, Khan A, Dorn G, and Hill NO: Human Leukocyte Interferon Trials in Leukemia and Cancer. Poster Session presented at Joint Meeting of the 18th Congress of the International Society of Hematology and 16th Congress of the International Society of Blood Transfusion, Montreal, Quebec, Canada, August 16-21, 1980.

84. Hill NO, Shorey J: Hbc Antigen and Antibody in Hepatitis B Surface Antigen Positive Blood Donors. Hepatitis Scientific Memoranda, July, 1980.

85. Hill NO, Pardue A, Aleman C, Dorn G, Hill JM: Clinical Trials of Interferon in Cancer and Viral Diseases. Presented at the Blackford Memorial Lectures, Denison, Texas, September 6, 1980.

86. Khan A, Hill NO: Interferon Treatment in Immuno-suppressed Patients. Annals of Allergy, Vol. 44, No. 5, May, 1980, 289.

87. Hill NO, Pardue A, Aleman C, Khan A, Dorn G, Hill JM: Clinical Trials with Interferon. Presented at Interphex 80, New York, N.Y., September 12-14, 1980.

88. Hill NO, Aleman C, Pardue A, Dorn G, Hill JM: Human Leukocyte Interferon Therapy of Leukemia and Cancer. Presented at the Mexican Society of Hematology Annual Meeting, November 10, 1980, Mexico City, Mexico.

89. Hill NO, Pardue A, Khan A, Aleman C, Hill JM: High Dose Human Leukocyte Interferon Trials in Leukemia and Cancer.

Presented at the 8th Annual Meeting of the Southeastern Cancer Research Association, November 12-14, 1980, Atlanta, Georgia.

90. Hill NO, Pardue A, Khan A, Aleman C, Dorn G, Hill JM: Phase I Human Leukocyte Interferon Trials in Cancer and Leukemia. Journal of Clinical Hematology and Oncology. Vol. 11, No. 1, 23-35, 1981.

91. Hill NO: Production and Characterization of Human Leukocyte Interferon. Interferons and Their Applications. (editor) Dr. Paul E. Came and Dr. William A. Carter, Springer-Verlag Publications, Spring, 1981.

92. Hill NO: IF, Its Efficacy and the Prospects for Leukocyte IF. Presented at the American Blood Resources Meeting, Washington, D.C., February 1, 1981.

93. Hill NO, Pardue A, Khan A, Hill RW, Aleman C, Hill JM, and Dorn G: Human Leukocyte Interferon Therapy of Leukemia and Cancer. Interferon Scientific Memoranda, February and March, 1981.

94. Hill NO, Pardue A, Khan A, Aleman C, Hill JM: High Dose Human Leukocyte Interferon Trials in Leukemia and Cancer. Medical and Pediatric Oncology, 9:82, 1981.

95. Hill NO: The Role of Human Leukocyte Interferon in the Advance of Hemotherapy. Presented at the South Central Association of Blood Banks Meeting, April 13, 1981, Oklahoma City, Oklahoma.

96. Hill NO, Khan A, Pardue A, Hilario R, Aleman C, and Hill JM: Interferon Alpha Trials in Leukemia and Cancer. Poster Session presented at The Biology of the Interferon System Meeting in Rotterdam, Holland on April 21-24, 1981.

97. Hill NO: Interferon and Genetic Engineering. Presented at the Southwest Foundations Meeting, San Antonio, Texas, April 8-9, 1981.

98. Hill NO, Pardue A, Khan A, Aleman C, Hilario R, and Hill JM: Clinical Trials of Human Leukocyte Interferon in Malignancy. Texas Reports on Biology and Medicine, The Interferon System: A Review to 1982 Part II, 634-640, Vol. 41, 1981-1982.

99. Hill NO: Production and Characterization of Human Leukocyte Interferons. In Interferons and Their Applications: In the Handbook of Experimental Pharmacology, Vol. 71, 259-268, 1984.
100. Khan A, Hansen B, Hill NO, Loeb E, Pardue A, Hill JM: Transfer Factor in the Treatment of Herpes Simplex Types 1 and 2. Dermatologica, 163, 177-185, 1981.
101. Khan A, Burt S, Hill NO, Hill JM: A Unique Antigen (Sigma) on Sezary Cells. (abstract) Journal of Clinical Hematology and Oncology, Vol. 1, No. 1, p. 37, Jan. 1981.
102. Khan A, Ayer R, Michaelson JD, Weaver RE, Hill NO: Transfer Factor Treatment un Bullous Pemphigoid: Impaired T Cell Function. Journal of Clinical Hematology and Oncology, Vol. 11, No. 1, p. 39, (abstract), Jan. 1981.
103. Khan A, Garrison O, Hill JM, Antonetti A, Hill NO, Gracy RW: Isolation and Characterization of Immopeptide from Dialyzable Leukocyte Extract (abstract) Journal of Clinical Hematology and Oncology, vol. 11, No. 1, p. 39, January, 1981.
104. Pichyangkul S, Hill NO, and Khan A: Purification of Lymphotoxin from RPMI-1788 Cell Line Supernate. In Human Lymphokines: Biological Immune Response Modifiers, (editors) Khan and Hill, Academic Press, p. 173, 1982.
105. Khan A, Hill NO, Ridgway H, and Webb K: Pre-Clinical and Phase I Clinical Trials with Lymphotoxin: in Human Lymphokines: Biological Immune Response Modifiers. (ed) Khan and Hill, Academic Press, p. 621, 1982.
106. Khan A, Weldon D, Duvall J, Pichyangkul S, Hill NO, Muntz D, Lanius R, and Ground M: A Standarized Automated Computer Assisted Micro-Assay for lymphotoxin: in Human Lymphokines: Biological Immune Response Modifiers, Academic Press, p. 9, 1982.
107. Khan A, Martin E, Webbe K, Weldon D, Hill NO, Duvall J, and Hill JM: Regression on Malignant Melanoma in a Dog by Local Injection of a Partially Purified Preparation Containing Human α -Lymphotoxin. Proc. Soc. Exp. Biol. Med., 169:291-294, 1982.
108. Hill NO, Pardue A, Khan A, Aleman C, Hilario R, Osher K, Hill JM: Ifn-Alpha Trials in Leukemia and Cancer. Presented at 13th International Cancer Congress, Seattle, Washington, September 8-15, 1982.

109. Hill NO: Hemotherapy in Cancer and Leukemia Patients. Presented at Texas Medical Association Hemotherapy Roundup, San Antonio, Texas, May 7, 1982.

110. Hill NO: Interferon. Presented at American Society of Medical Technology Meeting, Houston, Texas, June 22, 1982.

111. Hill NO, Pardue A, Khan A, Aleman C, Hilario R, Osther K, Hill RW, Hill JM: Interferon Alpha and Cimetidine Combination in Malignant Melanoma Plus Phase I Observations of Gamma Interferon Administration for Malignancy. Presented at the 3rd International Congress for Interferon Research, Miami, Florida, November 1-3, 1982.

112. Hill NO: Background to Human Interferon. In Recombinant DNA Products: Insulin Interferon-Growth Hormones. (editor) Dr. Arthur P. Bollon, CRC Press, 67-74, 1982.

113. Hill NO, Pardue A, Khan A., Aleman C, Hilario R, Osther K, Hill RW, Hill JM: Treatment of Malignant Melanoma with a Combination of Interferon Alpha and Cimetidine. Presented at American Society of Clinical Oncology, San Diego, California, May 22-24, 1983.

114. Hill NO, Pardue A, Khan A, Hill RW, Aleman C, Hilario R, Hill JM, Osther K: Interferon and Cimetidine for Malignant Melanoma. Letter to the Editor. New England Journal of Medicine, February 3, 1983.

115. Hill NO: Production and Characterization of Human Leukocyte Interferon. Handbook of Experimental Pharmacology. Interferons and Their Applications. (editor) P.E. Came and W.A. Carter, Vol. 71, 259-269, 1983.

116. Aota F, Chang D, Hill N, and Khan A: Monoclonal Antibody Against A Unique Promyelocytic Cell Line (HL-60). Exp. Hematol. 10:835-843, 1983.

117. Khan A, Grammer S, Chang D, Hill NO, and Miller J: Mouse Monoclonal Antibody (WI-MN-1) Against Malignant Melanoma, J. Cancer Res. 43:5868-5872, 1983.

118. Osther K, Georgiades J, Hirai N, Pardue A, Hilario R, Aleman C, Khan A, Shah S, Hill JM, Hill NO: Phase I and Phase II Trials with Human Gamma Interferon. The Biology of the Interferon System 1983: 527-533, 1983. E. DeMaeyer and H. Schellekens, editors.

119. Hill NO, Pardue A, Khan A, Aleman C, Hilario R, Osther K, Hill R, and Hill JM: Interferon Alpha and Cimetidine Combination in Malignant Melanoma. Presented at the International Symposium on Interferons held in Kyoto, Japan on October 3-6, 1983. Published in Interferons: Proceedings of the International Symposium on Interferons (editor Tsunataro Kishida) p 227-238.
120. Aota F, Nehashi Y, Kijima M, Osamura S, Sato H, Kobayashi S, Khan A, and Hill, NO: Sensitivities of Human Leukemia and Lymphoma Cells to Human Interferon-Alpha, Beta, and Gamma Before Clinical Applications. Presented before the International Symposium on Interferons held in Kyoto, Japan on October 3-6, 1983. Published in Interferons: Proceedings of the International Symposium on Interferons (editor Tsunataro Kishida) p 349-353.
121. Hill NO, Pardue A, Khan A, Aleman C, Hilario R, Osther K, Hill RW, and Hill JM: Treatment of Malignant Melanoma with a Combination of Interferon Alpha and Cimetidine. Presented at the Second International TNO Meeting on the Biology of the Interferon System, Rotterdam, Holland, April 18-22, 1983.
122. Aota F, Chang D, Hill NO, and Khan A: Monoclonal Antibody Against Myeloid Leukemia Cell Line (KG-1). Cancer Research 43, 1093-1096, March 1983.
123. Hirai N, Hill NO, Osther K: Temperature Influences on Different Human Alpha Interferon Activities. Journal of Interferon Research, 4:507-516 (1984).
124. Hirai N, Hill NO, Motoo Y, and Osther K: Cimetidine Enhances Interferon Induced Augmentation on NK Cell Activity and Suppresses Interferon Production. Acta Path. Microbiol. Immunol. Scand., Sect. C, 93: 152-159, 1985.
125. Hirai N, Hill NO, Motoo, Y, and Osther K: Antiviral and Antiproliferative Activities of Human Leukocyte Interferon Potentiated by Cimetidine In Vitro. Journal of Interferon Research, 5:375-382 (1985).
126. Berent SL, Torczynski RM, Hill NO Pichyangkul S, Jia F, Hill JM, Khan A, and Bollon AP: Expression and Analysis of Human Tumor Necrosis Factor. Advances in Gene Technology: Molecular Biology of the Endocrine System. Proceedings of the 18th Miami Winter Symposium, February 3-7, 1986, Miami, Florida, 100-101, Vol. 4.

127. Khan A, Pardue A, Aleman C, Dickson J, Pichyangkul S, Hill JM, Hilario R, and Hill NO: Phase 1 Clinical Trial with Recombinant Tumor Necrosis Factor (TNF). Presented before the American Society for Clinical Oncology March 5, 1986. Abstract in Proceedings of ASCO Vol. 5: 226, 1986.

128. Khan A, Joher A, Arfan M, Jia F, Pichyangkul S, Berent S, and Hill NO: Acute Toxicity and stability Studies on Tumor Necrosis Factor (TNF) in Mice. Presented before the American Association of Cancer Research. March 27, 1986. Abstract in Proceedings of the AACR Vol. 27: 320, 1986.

129. Khan A, Pardue A, Aleman C, Dickson J, Pichyangkul S, Hill JM, Hilario R, and Hill NO: Phase 1 Clinical Trial of Recombinant Human Tumor Necrosis Factor. Presented before the International Society of Hematology, Sydney, Australia, May 1986.

130. Hill NO, and Staples JW: Incidence of Antibody to the T-Cell Lymphotropic Virus (HTLV-I) in a Major Southwestern Region Blood Donor Population. Presented before the American Association of Blood Banks Annual Meeting, Kansas City, Missouri, 1988. Abstract in Transfusion 28 (Supplement), 215, 1988.

131. Hill NO, Staples JW, Laird-Fryer B, and Shaffer SL, Hepatitis C Virus Teleconference. Presented live by the South Central Association of Blood Banks, April 23, 1990 in Shreveport, Louisiana to enrolled hospital and blood center audiences nationwide.

132. Hill NO, Laird-Fryer B, and Staples JW: Recombinant Immunoblot Assay for Hepatitis C Virus. Presented on November 13, 1990 before the American Association of Blood Banks/ International Society of Blood Transfusion Joint Meeting, Los Angeles, California.

133. Hill NO: Hepatitis C after Needlestick Injuries. Annals of Internal Medicine. 1992; 116(4):345.

134. Hill, NO: Hepatitis C not incurable. Letter. Texas Medicine. October, 1998.